Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nektar Therapeutics presents positive clinical data from a Phase 1 study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin


Saturday, 18 Jan 2014 12:00pm EST 

Nektar Therapeutics:Says it has presented favorable data from a Phase 1 study of etirinotecan pegol (EP, NKTR-102) in combination with 5-fluorouracil (5-FU)/Leucovorin (LV) in patients with advanced cancer.Says NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics.Says these new data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco, California.Says the phase 1 study assessed the safety, pharmacokinetics and anti-tumor activity of NKTR-102 when given in combination with standard doses of 5-FU/leucovorin.Says data was presented from 26 patients enrolled in 5 cohorts in a standard dose escalation design.Says study established a recommended dose of 75 mg/m2 NKTR-102 in combination with standard doses of 5-FU/LV given every two weeks. 

Company Quote

12.07
 +0.00%
1 Oct 2014